Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership ...

Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...

The biopharmaceutical industry is grappling with a complex mid-year outlook in 2025, as accelerating innovation collides with ...

US biopharma Mineralys Therapeutics has announced positive topline data from its Phase II Explore-CKD trial evaluating the ...

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

EY today released its 35th annual Biotech Beyond Borders Report. This finds that the biopharma industry is currently at an ...

The UK’s National Institute for Health and Care Excellence (NICE) has today recommended Spevigo (spesolimab) for the ...

Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric ...

The US Food and Drug Administration has announced the Commissioner’s National Priority Voucher (CNPV) program aimed at ...

SunRock Biopharma has teamed up with China’s Escugen to co-develop SRB123, a first-in-class antibody-drug conjugate (ADC) targeting CCR9, an antigen which is tied to particularly hard-to-treat cancers ...

Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renmnibi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a ...